Vacca, Sekhri Join Versant’s Manhattan Biotech Incubator

Xconomy New York — 

Versant Ventures has appointed Joe Vacca and Paul Sekhri to executive roles at Highline Therapeutics, the firm’s Manhattan-based biotech startup incubator. Vacca, a Merck veteran, has joined up as Highline’s chief scientific officer. Sekhri, currently the president and CEO of Lycera—which Celgene has an option to acquire—has been named an operating partner at Highline. The incubator has formed one startup so far, Kyras Therapeutics, though Versant said in a press release that “several additional seed programs” are under development.